跳至主要内容
临床试验/NCT05726097
NCT05726097已完成3 期

Optimization of the Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure

Region Skane1 个研究点 分布在 1 个国家目标入组 147 人开始时间: 2023年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Region Skane
入组人数
147
试验地点
1
主要终点
Completeness rate

研究概览

简要总结

The study aims to investigate the effect of the optimized bowel preparation and boost regimens on colon capsule endoscopy procedures, specifically on cleanliness and completion rate.

详细描述

Colon capsule endoscopy (CCE) is a promising modality for lower gastrointestinal (GI) investigations in clinical routine and screening. Furthermore, the double-headed camera capsules are being applied for panenteric investigations, with promising results. The major limitation to its use has been finding a bowel preparation that will clean the colon adequately for good visualization of the mucosa and help propel the capsule using boosters through the colon. To achieve wider CCE adoption, challenges regarding completion rates (CR) and adequate cleanliness rates (ACR) must be handled. CR and ACR should be improved to meet the standards for optical colonoscopy (OC) from the European Society of GI Endoscopy (ESGE). ESGE recommends both CR and ACR ≥ 90%. Recently, a meta-analysis of preparation regimens for CCE confirmed that CR and ACR were suboptimal.

This study is designed to investigate the CR, ACR, and diagnostic yield (DY) of very low-volume polyethylene glycol (PEG) - based laxative compared to a conventional high-volume laxative and the use of different boosters.

All consecutive patients referred for colon capsule endoscopy will be enrolled in the study. PillCam® Crohn's capsule will be used. Patients will undergo a split-dose bowel preparation with a very low-volume PEG-based laxative. In the study arm nr1 gastrografin and magnesiumoxid + sodium picosulfate will be used. In the study arm Nr 2, the same regimen will be used but completed with 2 mg of prucalopride before ingesting the capsule. The results of the study arms will be compared to the previously used standard regimen with 4 L of PEG as a laxative and sodium phosphate as a booster.

The images from the colon capsule will be reviewed, and the quality of bowel preparation (cleanliness rates) and completion rate will be evaluated. Patient tolerance of the bowel preparations and diagnostic yield of colon capsule endoscopy using the different preparation regimens will also be evaluated.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Sequential
主要目的
Diagnostic
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subject referred for clinical colon/panenteric examination
  • •Subject received an explanation about the nature of the study and agreed to provide written informed consent

排除标准

  • •Subject with dysphagia or any swallowing disorder
  • •Subject with a prior stomach, small bowel, or colonic resection
  • •Subject with severe renal insufficiency
  • •Subject with any allergy or other known contraindication to the medications used in the study
  • •Women who are either pregnant or nursing
  • •Subject suffers from life threatening conditions

研究组 & 干预措施

Optimized preparation regimen

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster

干预措施: polyethylene glycol + ascorbic acid (Drug)

Optimized preparation regimen

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster

干预措施: magnesiumoxid + sodium picosulfate (Drug)

Optimized preparation regimen with prucalopride

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster + 2 mg of prucalopride

干预措施: polyethylene glycol + ascorbic acid (Drug)

Optimized preparation regimen with prucalopride

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster + 2 mg of prucalopride

干预措施: magnesiumoxid + sodium picosulfate (Drug)

Standard preparation regimen

Active Comparator

4 L polyethylene glycol as laxative 30 + 15 mL sodium phosphate as a booster

干预措施: sodium phosphate (Drug)

Standard preparation regimen

Active Comparator

4 L polyethylene glycol as laxative 30 + 15 mL sodium phosphate as a booster

干预措施: polyethylene glycol (Drug)

Optimized preparation regimen

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster

干预措施: gastrografin (Drug)

Optimized preparation regimen with prucalopride

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster + 2 mg of prucalopride

干预措施: gastrografin (Drug)

Optimized preparation regimen with prucalopride

Experimental

1 L polyethylene glycol + ascorbic acid as laxative and gastrografin and magnesiumoxid + sodium picosulfate as a booster + 2 mg of prucalopride

干预措施: prucalopride (Drug)

结局指标

主要结局

Completeness rate

时间窗: Within 3 months after completed capsule colonoscopy

Visualization of the hemorrhoidal plexus or an excreted capsule

Adequate cleanliness rate

时间窗: Within 3 months after completed capsule colonoscopy

Assessment of the quality of the bowel preparation using a the 4-point Leighton-Rex scale

次要结局

  • Transit times(Within 3 months after completed capsule colonoscopy)
  • Diagnostic yield(Within 3 months after completed capsule colonoscopy)
  • Assessment of patient tolerance of the bowel preparations(Within 3 months after completed capsule colonoscopy)

研究者

发起方
Region Skane
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验